Efficacy and Safety of Goreisan for Chronic Heart Failure Patients with Chronic Kidney Disease

Ryudo Kawahara; Koki Chiba; Hiroko Takahashi; Kazuhiko Nara; Koichiro Tanaka; Tomoyuki Ata; Hiroshi Hashidomi; Hiroshi Doumae

Return

Efficacy and Safety of Goreisan for Chronic Heart Failure Patients with Chronic Kidney Disease

VernacularTitle:慢性腎臓病合併慢性心不全患者における五苓散の有用性と安全性の臨床的検討
Author: Ryudo KAWAHARA ¹ ; Koki CHIBA ² ; Hiroko TAKAHASHI ² ; Kazuhiko NARA ² ; Koichiro TANAKA ² ; Tomoyuki ATA ² ; Hiroshi HASHIDOMI ¹ ; Hiroshi DOUMAE ¹
Author Information

1. Department of Cardiology, Tokyo Nishi Tokushukai Hospital
2. Department of Traditional Japanese Medicine, Faculty of Medicine, School of Medicine, Roho University
Keywords: heart failure; chronic kidney disease; goreisan
From:Kampo Medicine 2019;70(1):57-64
CountryJapan
Language:Japanese
Abstract: Although evidence of Western therapy for heart failure has been established, evidence of treatment for heart failure with chronic kidney disease (CKD) has still not been established. The efficacy of additional Oriental medicine to standard therapy for heart failure with CKD is unclear. To address this issue, we retrospectively evaluated 20 consecutive heart failure patients with CKD (≧stage 3) who were orally administered goreisan (7.5 g/day) due to insufficient efficacy of standard therapy in our hospital from November 2015 to December 2017. We assessed symptoms, chest X-ray, BNP concentration, serum electrolytes, eGRF, plasma osmolality, and side effects. Goreisan improved heart failure in 11 of 20 patients, did not significantly deteriorate renal function, plasma osmolality, and did not clinically affect electrolytes. In conclusion, the present study suggested that additional use of goreisan to Western standard therapy is safe and useful for heart failure with CKD.